Stephens Investment Management Group LLC Purchases 9,670 Shares of IDEXX Laboratories, Inc. $IDXX

Stephens Investment Management Group LLC increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 8.8% during the third quarter, HoldingsChannel.com reports. The fund owned 119,824 shares of the company’s stock after buying an additional 9,670 shares during the period. Stephens Investment Management Group LLC’s holdings in IDEXX Laboratories were worth $62,571,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Aurora Investment Managers LLC. purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at $2,442,000. National Pension Service lifted its holdings in shares of IDEXX Laboratories by 5.6% during the 2nd quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after buying an additional 6,885 shares during the period. Howard Capital Management LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth $1,249,000. NewEdge Advisors LLC boosted its stake in shares of IDEXX Laboratories by 60.9% in the 1st quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock worth $8,552,000 after buying an additional 5,761 shares during the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock worth $11,988,000 after buying an additional 1,074 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.2%

IDEXX Laboratories stock opened at $698.47 on Thursday. The firm has a 50 day moving average of $572.78 and a 200 day moving average of $573.79. The firm has a market capitalization of $55.03 billion, a price-to-earnings ratio of 47.10 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the firm earned $3.22 earnings per share. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on IDXX shares. Barclays reduced their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Morgan Stanley increased their target price on IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Citigroup raised their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. BTIG Research dropped coverage on IDEXX Laboratories in a research note on Friday, October 30th. They set a “buy” rating for the company. Finally, Jefferies Financial Group cut their price target on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $717.27.

View Our Latest Research Report on IDEXX Laboratories

Insider Transactions at IDEXX Laboratories

In other news, insider Jonathan Mazelsky sold 25,140 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $703.19, for a total transaction of $17,678,196.60. Following the sale, the insider directly owned 83,803 shares in the company, valued at $58,929,431.57. This trade represents a 23.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sharon Underberg sold 8,906 shares of the firm’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the sale, the executive vice president owned 7,169 shares in the company, valued at $4,936,501.71. The trade was a 55.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 41,428 shares of company stock valued at $28,567,934. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Featured Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.